Randomized, double-blind, placebo-controlled trial of Etanercept (all
patients will initially be started on prednisone)
Types & Number of IIM Studied:
Active, new adult dermatomyositis (N = 30)
Entry Criteria:
Definite Dermatomyositis
IMACS Core Set Measures Included:
Physician and Patient Global Activity Assessments, Manual Muscle Testing,
Health Assessment Questionnaire
Other Measures Included:
Cutaneous Assessment Disease Activity Severity Index (CDASI), pulmonary
function testing, electrocardiogram, MVICT, magnetic resonance imaging,
skin biopsy; DNA microarrays on muscle, skin, and peripheral white
blood cells
Primary Outcome:
Cumulative dose of prednisone; Number of treatment failures; Responsiveness
of IMACS outcome variables
|